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Abstract 
Eph receptors are a subfamily of receptor tyrosine kinases. Eph receptor-mediated forward and ephrin ligand-
mediated reverse signalings are termed bidirectional signaling. Increasing evidence shows that Eph/ephrin signaling 
regulates cell migration, adhesion, morphological changes, differentiation, proliferation and survival through cell–cell 
communication. Some recent studies have started to implicate Eph/ephrin signaling in tumorigenesis, metastasis, and 
angiogenesis. Previous studies have shown that EphB1 receptor and its ephrin ligands are expressed in the central 
nervous system. EphB1/ephrin signaling plays an important role in the regulation of synapse formation and matu-
ration, migration of neural progenitors, establishment of tissue patterns, and the development of immune organs. 
Besides, various recent studies have detected the abnormal expression of EphB1 receptor in different brain tumors. 
However, the underlying molecular mechanisms of EphB1/ephrins signaling in the development of these tumors are 
not fully understood. This review focuses on EphB1 that has both tumor-suppressing and -promoting roles in some 
brain tumors. Understanding the intracellular mechanisms of EphB1 in tumorigenesis and metastasis of brain tumors 
might provide a foundation for the development of EphB1-targeted therapies.
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Background
Erythropoietin-producing hepatocellular carcinoma 
(Eph) receptors are a subfamily of receptor tyrosine 
kinases (RTKs) [1, 2]. Each Eph receptor includes a kinase 
domain, sterile alpha motif (SAM), PDZ-binding motif, 
juxtamembrane segment in the intracellular region, 
two fibronectin type III domains and an ephrin-binding 
domain in the extracellular region [3, 4]. In the human 
genome, the Eph receptor families include ten EphA 
receptors and six EphB receptors [4]. The structural dif-
ference between EphA and EphB receptors is that the 
former promiscuously binds glycosylphosphatidylinosi-
tol-linked ephrin-A ligands, whereas the latter promiscu-
ously binds transmembrane ephrin-B ligands [3].
One of the distinctive characteristics of Eph/ephrin 
signaling is its ability to initiate both Eph-mediated for-
ward and ephrin-mediated reverse signaling, termed 
bidirectional signaling [2]. Bidirectional propagation of 
signals requires the interaction between Eph receptors 
and ephrin ligands at sites of cell–cell contact because 
both are expressed at the cell surface [4] (Fig.  1). Eph-
mediated forward and ephrin-mediated reverse signaling 
are dependent on the kinase activity of Eph receptors and 
ephrin ligands, respectively [5] (Fig.  2). In detail, Eph/
ephrin forward signaling is initiated by ephrin ligand 
binding followed by the activation of tyrosine kinase 
domain of Eph receptor, and propagates in the Eph 
receptor-expressing cells while Eph/ephrin reverse sign-
aling is triggered by Eph receptor binding followed by the 
activation of Src family kinase domain of ephrin ligand, 
and propagates in the ephrin ligand-expressing cells [6]. 
It should be noted that Eph receptors and ephrin ligands 
also signal independently of each other (Fig.  2). Never-
theless, in addition to ephrin/Eph interactions, other 
RTKs and adhesion molecules are involved in ligand-
dependent or-independent crosstalk [4].
Eph receptors and ephrin ligands are expressed in most 
of cell and tissue types, and cell–cell communication 
mediated by Eph/ephrin signaling is implicated in various 
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cellular behaviors, such as cell migration, adhesion, mor-
phological changes, differentiation, proliferation, and 
survival [3]. It has been best characterized that Eph/
ephrin signaling is involved in axonal guidance, position-
ing of cell populations, formation of synaptic connections 
and neuronal connections [3]. Recent works have begun 
Fig. 1 Domain structure of Eph receptors and ephrins. SAM sterile alpha motif, PSD95 PDZ-postsynaptic density 95, Dlg discs large, ZO-1 zonula 
occludens-1
Fig. 2 Schematic representation of Eph/ephrin bidirectional signaling. Eph receptors and ephrin ligands signal dependently or independently of 
each other
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to address the functions of Eph/ephrin signaling in vas-
culogenesis, bone remodeling, immune modulation and 
stem cell differentiation. Although considerable progress 
has made in our understanding of the functions of Eph/
ephrin signaling in a variety of developmental processes, 
its roles in cancer metastasis, invasion and angiogenesis 
remain elusive [7]. In this review, we focus on the roles 
of EphB1/ephrins signaling in malignant brain tumors. 
More detailed information on the roles of EphA and 
other EphB receptors in tumorigenicity can be found in 
other recent reviews [2, 3, 6–8].
EphB1 in normal nerve tissue
Eph receptors and ephrin ligands are widely expressed 
in all adult organs with certain organ-specific patterns. 
It has been shown that both Eph receptors (B1, B2, B3) 
and ephrin ligands (B1, B2, B3) are expressed in the 
central nervous system such as the adult olfactory bulb, 
hippocampus, and cerebellum [9]. Real-time reverse 
transcription polymerase chain reaction (RT-PCR) anal-
ysis has indicated that EphB1, EphA6, and EphA8 are 
most prominent in the brain and testis [10]. Increasing 
evidences have demonstrated the involvement of ephrin 
ligands and Eph receptors in the regulation of synapse 
formation and maturation, migration of neural progeni-
tors, topographic maps, establishment of tissue patterns, 
and plasticity in distinct regions of the developing brain 
[11].
Development and maturation of synapses
Over the last few years, the functions of Eph receptors 
and ephrins have been delineated in the development 
and maturation of synapses [12] (Table  1). It has been 
reported that EphB1, EphB2, and EphB3 are involved in 
dendritic spine morphogenesis and synapse formation in 
the hippocampus. In particular, EphB1 and EphB2 play 
the major roles in this process [13]. EphB2/ephrin-B2 for-
ward signaling induces phosphorylation, ubiquitination 
and degradation of Ephexin-5, which has been shown to 
negatively regulate excitatory synapse development [14]. 
Furthermore, Eph receptors and ephrin ligands also play 
an important role in contact-dependent neuron–astro-
cyte communication at synapses [15].
Regulation of neural progenitors
EphB1 is required for neurogenesis and migration of 
neural progenitors (Table  1). For instance, EphB1 and 
ephrin-B3 cooperatively regulate the proliferation and 
migration of neural progenitors in the hippocampus [16]. 
A lack of EphB1 significantly reduces the number of neu-
ral progenitors and nestin-positive stem cells in the hip-
pocampus, disrupts proper migration and organization 
of neural progenitors, and affects other aspects of neuro-
genesis such as polarity, cell positioning and proliferation 
[16]. Furthermore, a recent study has indicated that mice 
lacking EphB1 and EphB2 display a positioning defect 
of CA3 hippocampal pyramidal neurons. EphB1 is also 
Table 1 Summary of EphB1/ephrins functions in part of tissues and cell lines
a Represents central nervous system
b Represents retinal ganglion cell
Tissue and cell Tissue and cell type Expression EphB1 functions Ligand-dependent Refs.
CNSa Normal CNS tissue Positive Involved in synapse formation in the  
hippocampus
Dependent [13]
CNS Normal CNS tissue Positive Involved in neurogenesis of neural  
progenitors
Dependent [16]
CNS Normal CNS tissue Positive Involved in rerouting RGCb projections Dependent [17]
CNS Normal CNS tissue Positive Increases expression of Nurr1 Dependent [18–20]
P19 Embryonic carcinoma cell Positive Promotes cell growth and migration Dependent [50]
U87 Glioma cell Undetectable Inhibits cell migration and invasion after over-
expression
Dependent [26]
U251 Glioma cell Undetectable Inhibits cell migration and invasion after over-
expression
Dependent [26]
Daoy Medulloblastoma Overexpressed Promotes cell growth and migration Unknown [48–51]
HEK 293T Stable cell line expressing 
ephrin-B1
Overexpressed Induces the activation of C-Jun N-terminal 
kinase activation
Dependent [44]
U87 Glioma cells transfected  
with ephrin-B2
Overexpressed Stimulates the migration and invasion Unknown [41]
Striatal anlage Normal CNS tissue Positive Involved in the migration of two sets of 
neurons
Dependent [25]
CNS Normal CNS tissue Positive Regulates the proliferation and migration of 
neural progenitors
Dependent [16]
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specifically required for rerouting retinal ganglion cell 
(RGC) projections ipsilaterally [17].
Nurr1
Ligand-activated EphB1 regulates the development of 
the neuronal system by increased expression of Nurr1, 
which promotes dopaminergic neuron differentiation, 
neuronal survival, axonal growth arrest, and synapse for-
mation [18–20]. Previous studies have found that EphB1 
recruits Nck to stimulate the JNK pathway that promotes 
Nurr1 expression by binding to the AP1/c-jun binding 
site in the 5′-flanking region of the Nurr1 gene [21]. In 
addition, EphB1 receptor upregulates the expression of 
N-methyl-D-aspartate receptors and leads to the forma-
tion of membrane ion channels [22, 23]. Ion channels 
are permeable to Ca2+ that binds to the cAMP response 
element (CRE)-binding site on Nurr1 and stimulates its 
expression [24].
EphB1 ligands
Ephrin-B1, ephrin-B2 and ephrin-B3 are the major 
ligands recognized by the EphB1 receptor (Table  1). 
EphB1/ephrins reverse signaling has a distinctive effect 
on neurons produced at the same time and site. As an 
activator, it can act as a repulsive signal for migrating 
cortical neurons [25]. However, EphB1/ephrins reverse 
signaling can also inhibit the migration of striatal neu-
rons [25]. The difference in the downstream molecular 
machinery of neurons may contribute to the different 
physiological responses of the same ligand/receptor com-
bination [25].
EphB1 in immune system
Eph/ephrin signaling is implicated in the development of 
immune organs. For example, ephrin-B1 and ephrin-B2 
can stimulate T cells and regulate thymocyte develop-
ment [26, 27]. Further study found that the deletion of 
ephrin-B1 and/or ephrin-B2 in thymocytes or thymic 
epithelial cells (TECs) leads to a decrease of medul-
lary areas and an enlargement of cysts [28]. However, 
the knockout of ephrin-B1 or ephrin-B2 in mice has no 
influence on the activation and proliferation of T cells 
and native CD4 cells, suggesting that other members of 
ephrin family may compensate the function of ephrins 
[26, 27]. Moreover, EphB2 and its ligands, ephrin-B1 and 
ephrin-B2 play a role in T cell progenitor migration [29]. 
Furthermore, EphB2 and EphB3 are required for the sur-
vival of the TECs and their absence will lead to a decrease 
of thymic cells and a reduction in volume of gland [30].
The knowledge about the role of EphB1/ephrin in 
immune system is limited. Previous study found that 
ephrin-B1 is highly expressed in peripheral blood lym-
phocytes (PBLs) derived from patients with rheumatoid 
arthritis (RA) [31]. Ephrin-B1 and EphB1 play an impor-
tant role in the inflammatory condition of RA through 
influencing the function of T cells [31]. For instance, 
ephrin-B1 can activate EphB1 and stimulate the produc-
tion of TNF-alpha in PBLs and IL-6 in synovial cells [31]. 
The function of EphB1/ephrin signaling in the develop-
ment of immune organs and the corresponding mecha-
nism of immune regulation are worth studying in the 
future. It is also promising to investigate whether the 
immune response initiated by EphB1/ephrin signaling is 
involved in tumorigenicity of brain tumors.
Tumor‑suppressing roles of EphB1
EphB1/ephrins signaling has perplexing dichotomous 
roles with tumor-suppressing and -promoting functions 
depending on the cellular context (Table 1).
EphB1 suppresses glioma motility
The functions of EphB1/ephrins signaling in glioma 
are now beginning to be uncovered. Using large-scale 
data from the International Cancer Genome Consor-
tium (ICGC) (https://dcc.icgc.org), it can be found that 
EphB1 alterations were observed in 4 of 268 glioma sam-
ples (1.49%), including 2 synonymous mutations and 2 
missense changes. An in  vivo analysis showed that the 
mRNA level of EphB1 expression did not vary across dif-
ferent glial tumor grades except for the increased expres-
sion level of EphB1 in oligodendroglioma compared with 
normal brain specimens. Moreover, survival analysis 
indicated that glioblastoma multiforme (GBM) patients 
with higher EphB1 expression level show longer survival 
rates [32]. It is proposed that ligand-dependent EphB1 
signaling appears to serve as a negative regulator of gli-
oma cell motility, and its high expression is a positive 
predictor for survival of GBM patients [32].
Quantitative real-time PCR and western blotting 
assays indicated that U87 and U251 glioma cells display 
low levels of mRNA and undetectable protein of EphB1 
[32]. Migration and invasion assays showed that forced 
overexpression of EphB1 in U251 cells effectively inhib-
its the cell migration and invasion upon ephrin-B2 ligand 
stimulation. These results indicated that enhanced EphB1 
forward signaling decreases the migration and invasion 
of glioma, which may be associated with the survival of 
GBM patients [32] (Fig.  3). This is similar to the roles 
of EphB4. Previous studies showed that overexpression 
of EphB4 involves in tumor progression by promoting 
angiogenesis, increasing survival, and promoting inva-
sion and migration [33, 34]. However, these effects can 
be inhibited in the presence of ephrin-B2 ligand, suggest-
ing that ligand-dependent EphB4 has the tumor suppres-
sion role [33, 34]. Furthermore, EphB1 inhibits ephrin-B2 
induced migration and invasion in U87 and U251 cells. 
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However, the underlying action mechanism of EphB1 in 
glioma remains elusive.
Hypermethylation
A reduction in EphB1 expression level was detected in 
a wide array of types of tumors such as glioma, gastric 
cancer, colorectal cancer, ovary serous carcinoma, and 
renal cell carcinoma [32, 35–38]. The mechanism that 
causes the decrease of EphB1 expression in these tumors 
remains unclear. One possible reason may be due to 
alternation of hypermethylation in CpG islands located 
in EphB1 promoter. The alternation of hypermethyla-
tion in promoter regions can influence gene expression 
levels in both normal and tumor cells. There is evidence 
for direct regulation of Eph receptors and ephrin ligands 
expression by methylation modifications. For example, 
hypermethylation of the promoter regions of almost all 
Eph receptors and ephrin ligands, including EphB1 and 
ephrin-B2, has been found in acute lymphoblastic leu-
kemia bone marrow samples and cell lines [39]. A recent 
study demonstrated an inverse correlation between the 
expression of EphB1 transcripts and EphB1 promoter 
methylation in pediatric acute myelogenous leukemia 
[40].
Ephrin–Eph complexes
Another possible reason for the decrease of EphB1 
expression in some tumors may be that ephrin–Eph com-
plexes can be processed by various mechanisms. The 
first mechanism involves protease-mediated degrada-
tion of ephrin–Eph complexes. A recent study indicated 
that phosphatase with tensin homology (PTEN) not only 
impairs EphB1-dependent cell attachment and migra-
tion, but also releases tyrosine phosphatases and ubiq-
uitin ligase Cbl to degrade EphB1 [41]. This finding is 
consistent with previous studies that found that Cbl can 
be recruited to ephrin–Eph complexes and then dephos-
phorylate and degrade the receptor proteins, resulting in 
termination of Eph/ephrin signaling [41–44]. Moreover, 
membrane-anchored membrane type-1 matrix metallo-
proteinase (MT1-MMP) has been found to cleave EphA2 
and trigger intracellular EphA2 translocation, leading to 
increased RhoA activity, cell junction disassembly, and 
single cancer cell invasion via cell repulsion [45]. It is 
unknown whether MT1-MMP also has certain effect on 
the EphB1 receptor. Another mechanism involves endo-
cytosis mediated by cell membrane-derived vesicles, 
which leads to the removal of ephrin–Eph complexes 
from the cell surface [46].
Ephrin-B2 reverse signaling in glioma
Interestingly, ephrin-B2 reverse signaling triggers dra-
matic morphological changes and increases cell motility 
[32, 47]. Microarray technology and immunohistochem-
istry assay indicated that level of ephrin-B2 mRNA is 
significantly higher in GBM than in normal brain, and 
associated with short-term survival in malignant astro-
cytomas. Forced expression of ephrin-B2 stimulates the 
Fig. 3 Putative model of the functions of EphB1/ephrins signaling in brain tumors. EphB1 kinase has three signaling pathways. EphB1 is phospho-
rylated upon stimulation by ephrin-B2. This forward signaling suppresses the motility of glioma cell lines U87 and U251. However, it also promotes 
the migration of medulloblastoma cell line DAOY via an unknown mechanism. Ephrin-B2 reverse signaling induces glioma cell migration independ-
ent of EphB1 binding. P tyrosine phosphorylation
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migration and invasion in the U251 cells [48]. However, 
EphB1 partially abrogates the migration and invasion 
induced by ephrin-B2 reverse signaling in glioma cells 
[32]. It is unclear which molecules are implicated in 
the phenotypic changes of glioma cells downstream of 
ephrin-B2 and how EphB1-ephrin-B2 interactions coop-
eratively regulate the cellular behavior of glioma cells.
A previous study has shown that ephrin-B2 con-
trols cell motility and adhesion during blood vessel wall 
assembly by EphB4-ephrin-B2 interactions that recruit 
the adaptor molecule Crk and p130 (Cas) signaling com-
plex to reduce cell motility [49]. Cho et  al. found that 
activation of ephrin-B1 by EphB1/Fc can lead to JNK acti-
vation, which is a downstream event of ephrin-B reverse 
signaling. A further study showed that ephrin-B1 inter-
acts with CNK1 and promotes cell migration through 
RhoA-dependent JNK activation [50]. Recent study dem-
onstrated that ephrin-B2 control vessel pruning through 
STAT1–JNK3 signalling and plays a important role in the 
endothelial cell survival [51]. The Src kinase could posi-
tively regulate ephrinB phosphorylation whereas tyrosine 
phosphatase PTB-BL could de-phosphorylate ephrin-B2 
[52]. The signals inducing ephrin-B2 de-phosphorylation 
will lead to endothelial cell death. Future studies will 
be needed to determine whether EphB1 interacts with 
these phosphatases and kinases to regulate the ephrin-
B2 reverse signaling. In addition, it has been proposed 
that the feedback loop mechanism of Eph/ephrin sign-
aling exists in glioma cells. For instance, ephrin-A1 sup-
presses EphA2 expression and vice versa, thus regulating 
cell migration and invasion [1]. Ephrin-B1 also decreases 
EphB2 expression levels by inducing EphB2 internaliza-
tion and degradation [6, 53]. It also needs to be deter-
mined whether the feedback between EphB1 and ephrin 
exists in glioma cells.
By now, the direct evidences that clarify the mecha-
nism of EphB1 in inhibiting glioma cell migration and 
invasion are limited. We are now designing experiments 
to determine the detailed action mechanism of EphB1 in 
inhibiting the migration of glioma cells.
Tumor‑promoting roles of EphB1
In addition to the tumor-suppressing roles of EphB1 
in diverse tumor types, it controversially has tumor-
promoting roles. The different roles of EphB1 in tumor 
development can be partially explained by the fact that 
the function of Eph receptors is highly context-depend-
ent and can vary across cancer types [6].
EphB1 promotes tumorigenesis in medulloblastoma
In addition to the tumor-suppressing role in glioma, 
EphB1 also promotes tumorigenesis in medulloblas-
toma [54]. A recent study found that mRNA and protein 
expression levels of EphB1 are high in human medul-
loblastoma cell lines Daoy and UW228. EphB1 knock-
down in Daoy using siRNA assay reduces cell growth 
and migration, decreases the expression of important cell 
cycle regulators, and increases the percentage of cells in 
G1 phase of the cell cycle [54, 55]. These changes in cell 
physiology due to EphB1 knockdown can be explained in 
part by the decrease in the expression levels of cyclin E, 
PCNA, and AKT [54] (Fig. 3). Moreover, EphB1 knock-
down decreases β1-integrin expression and phosphoryl-
ated Src levels, which is consistent with a previous study 
indicating that EphB1 regulates cell migration and chem-
otaxis via stimulation of c-Src activity [54, 56] (Fig.  3). 
Furthermore, EphB1 can functionally interact with the 
epidermal growth factor receptor (EGFR), contribut-
ing to the metastatic behavior of medulloblastoma cells 
[54, 57]. Importantly, EphB1 knockdown can enhance 
the sensitivity of medulloblastoma to ionizing radiation 
sensitivity in  vitro and in  vivo [54]. It should be noted 
that IDH mutation status of diffuse gliomas is required 
for proper subclassification [58]. Up to now, studies of 
Ephrin/Eph have not determined whether tumor biology 
differs according to IDH status.
Tumor-promoting mechanisms
Previous studies utilized some cell lines, such as P19 
cells, human renal microvascular endothelial cells, and 
CHO cells, to explore the action mechanism of EphB1 in 
cell migration and invasion. Increasing evidence suggests 
that the EphB1 and ephrin complex functions in coopera-
tion with other signaling molecules to regulate cellular 
behaviors.
Grb2
It has been determined that EphB1 recruits adaptor pro-
teins and promotes cell migration (Fig.  4). For instance, 
activated EphB1 recruits adaptor protein Grb2 and p52Shc, 
and promotes phosphorylation of p52Shc and c-Src, 
whereby their concerted actions activate MAPK/ERK and 
regulate events involved in cell motility (Fig. 4) [56]. Grb2 
has been known to be associated with tyrosine phos-
phorylated EGFRs and platelet-derived growth factors 
(PDGFRs) through its Src homology 2 (SH2) domain and 
couples the receptor tyrosine kinase to Ras signaling [59].
Grb7
In addition to Grb2, the interaction between EphB1 and 
adaptor protein Grb7 plays a role in the regulation of cell 
migration (Fig. 4) [60]. SH2 domain of Grb7 can interact 
with FAK, and involve in intergrin-mediated cell migra-
tion [61, 62]. Interestingly, FAK also recruits many signal-
ing molecules, such as Grb2, Grb7, Src and PI3K, to local 
contacts and stimulate the cell migration (Fig. 4) [63].
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Signaling complex
Ligand-activated EphB1 forms a signaling complex with 
Nck, paxillin, and FAK, and induces tyrosine phospho-
rylation of paxillin in a c-Src-dependent manner (Fig. 4) 
[64]. The biological function of paxillin coordinated 
signaling may involve in the regulation of cell spreading 
and motility [65]. Taken together, these data suggest that 
Grb2, Grb7, integrins, Nck, NIK, Src, paxillin and other 
adaptor proteins play essential roles in cell migration 
mediated by EphB1/ephrins signaling.
These accumulated data have lead to a better under-
standing of the roles of EphB1 in cell motility. More stud-
ies are still required to comprehensively elucidate the 
crosstalk between EphB1 with these signaling molecules 
for understanding the action mechanism of EphB1 on the 
migration and invasion of tumor cells.
Tumor microenvironment
Tumor microenvironment is an emerging research field 
of tumor biology in recent years. It is mainly character-
ized by hypoxia, angiogenesis, lower extracellular pH in 
tumor tissues [66]. The roles of EphB1/ephrin signaling 
in tumor microenvironment are less known by now.
Hypoxia
Previous studies have shown that the mRNA and pro-
tein expression levels of hypoxia inducible factor (HIF)-1 
alpha, vascular endothelial growth factor (VEGF), EphB4, 
ephrin-B2, EphA2 and ephrin-A1 are increased in the 
skin upon of induction of hypoxia while knockdown of 
HIF-1alpha leads to an abolishment of up-regulation 
of Eph receptors and ephrin ligands [67, 68]. However, 
another study observed that hypoxia has no effect on the 
Eph/ephrin expression in human melanoma cells in vitro 
[69]. The relationship between the protein expres-
sion of Eph/ephrin and hypoxia condition remains elu-
sive. Moreover, it has been known that dysregulation of 
ephrin/Eph may influence the cell–matrix and cell–cell 
attachment, and organization of the cytoskeleton, which 
can increase tumor cell invasion and metastasis. For 
instance, ephrin ligand and Eph receptor may interact 
with adhesion molecule E-cadherin and affect cell–cell 
attachment [70, 71].
Angiogenesis
Eph/ephrin signaling plays a key role in the angiogenesis 
of some tumors. Tumor angiogenesis plays an impor-
tant role in the metastasis and carcinogenesis. Previ-
ous study have found that ephrin-B2 reverse signaling is 
implicated in endothelial cell sprout and tip cell genera-
tion and elongation [72]. It has also been determined that 
EphB4 and ephrin-B2 mRNAs were expressed at sites of 
neovascularization of human glioma while the ephrin-B1 
was only detected in the proximity of vessels, suggest-
ing the functional interaction between Eph receptors 
and ephrin ligands expressed on endothelial and glioma 
cells, respectively [73]. Moreover, the truncated and sol-
uble EphB4 receptor prompts tumor angiogenesis upon 
stimulating ephrin-B2 signaling [48]. In contrast, solu-
ble ephrin-B2-Fc molecule suppresses growth of head 
and neck squamous cell carcinoma xenografts by induc-
ing maturation/stabilization of vessels in the tumor [74]. 
Fig. 4 Cellular proteins interacting with EphB1. Ligand-activated EphB1 recruits adaptor proteins Grb2, Grb7, Nck and paxillin, and is involved in cell 
migration and adhesion
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Furthermore, ephrin-B2 is involved in the angiogenesis 
induced by VEGF signaling pathway by facilitating VEGF 
receptor internalization [75].
EphB1 receptor as a potential therapeutic target 
in brain tumors
Certain molecules have been developed to specifically 
target Eph/ephrin bidirectional signals, such as antago-
nistic antibodies, peptides, and recombinant proteins 
[76–79]. The high expression level of EphB1 in part of 
brain tumors, like medulloblastoma, has raised inter-
est in exploring new strategies to target EphB1 receptors 
for cancer therapy. For instance, the molecules to inhibit 
EphB1 kinase signaling, such as ligand-blocking anti-
bodies and peptides, can be used as antagonists [76, 77, 
80]. Moreover, radiation therapy could be used in com-
bination with knockdown of EphB1 by RNA interference 
technique to enhance cellular radiosensitization of tumor 
cells [54]. Another future research direction will be the 
use of cytotoxic payloads delivered by antibody–drug 
conjugates to interfere with EphB1/ephrins signaling for 
inhibiting tumor cell growth [79, 80]. It should be noted 
that the blood–brain barrier (BBB) might influence the 
availability of the biologic drugs in the brain. Therefore, 
the new methods should be developed to cross the BBB. 
For instance, drugs can bypass the BBB by conjugat-
ing with a monoclonal antibody against the transferrin 
receptor, injecting the effective cell-penetrating peptides, 
or using focused ultrasound and circulating microbub-
bles [81–83]. Further in vitro and in vivo studies are still 
needed to determine whether these approaches are effec-
tive treatments for some brain tumors.
Conclusions
The action mechanism of EphB1/ephrins signaling 
appears to be complex in normal central nervous tissue 
and brain tumors. EphB1/ephrins signaling is not only 
implicated in suppressing tumor migration and invasion, 
but also promoting tumor development. By now, our 
understanding on the complicated functions of EphB1/
ephrins signaling in brain tumors is still limited, and 
more studies are urgently needed to resolve the confus-
ing and controversial events. First, appropriate studies 
are crucial to decipher the paradoxes of EphB1/ephrins 
signaling in different cellular contexts during the devel-
opment of a variety of brain tumors. In particular, it is 
worth exploring the unknown molecular mechanisms 
of EphB1, such as genetic and epigenetic modifications, 
downstream signaling pathways, the feedback loop 
between the ligands and receptors, and the protein deg-
radation process of EphB1, to expand our knowledge 
about the molecular pathogenesis of brain tumors [32]. 
Moreover, it will be important to investigate whether 
EphB1 mutations widely exist in brain tumor patients and 
the effect of these mutations on tumorigenesis. Recent 
studies have found gene mutations in the kinase domain 
of EphA3 in colorectal cancer cells [4]. Furthermore, it is 
essential to explore the correlation of EphB1 expression 
levels with the clinical outcomes of various brain tumor 
types in order to determine whether EphB1 is a favora-
ble prognostic predictor for patients. In conclusion, the 
roles of EphB1/ephrins signaling in brain tumors are only 
beginning to be explored, and further studies will gener-
ate more comprehensive data.
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